Suzhou’s MabSpace Biosciences filed an IND application with the CFDA last month to begin human testing of a second-generation PD-L1 antibody. MSB2311 is the world’s first PD-L1 candidate with pH-dependent antigen binding property. In addition, MabSpace has built a portfolio of six immune-oncology antibodies to work in combination with MSB2311. MabSpace owns global rights to MSB2311, its lead candidate.
Source: China Biotoday
